Rheumatoid arthritis (RA) is a chronic autoimmune disease that has a worldwide prevalence of 1%. The symptoms of RA are pain, stiffness and symmetrical synovitis of diarthrodial joints, which result in articular destruction, functional decline, and substantial comorbidity in the cardiovascular, neurologic and metabolic systems. 1 In RA, fibroblast-like synoviocytes (FLS, Type B synoviocytes) and osteoclasts are the main cells that contribute to bone and cartilage degradation, respectively. 2 Pro-inflammatory cytokines, including interleukin-1β (IL--1β), tumor necrosis factor-α (TNF-α) and IL-6, play an essential role in the activation of FLS and the differentiation of osteoclasts, which have been implicated in the pathogenesis of RA. 3 Targeting pro-inflammation cytokines and blocking their signal pathways have become an important strategy in RA treatment. The major functions of TNF-α in RA are associated with the production of pro-inflammation cytokines, inflamed synovium, chemokine amplification, Treg cells and osteoclast recruitment. 4 As a TNF inhibitor, etanercept 5 is a human recombinant version of the soluble p75 TNF receptor that is linked to the Fc of human immunoglobulin G subclass 1 (IgG1), and it acts as a competitive inhibitor of the binding of TNF-α to cell-surface TNF receptors and thereby inhibits TNF-α-induced pro-inflammatory activity in the joints of RA patients. It was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumor necrosis factor inhibitor to be approved for use in rheumatic diseases. In recent years, four anti-TNF therapies, infliximab, adalimumab, certolizumab and golimumab, have also been approved for the treatment of RA. 6 In RA, IL-6 is responsible for the activation of immune cells, endothelial cells, synoviocytes, and osteoclasts and for the production of acute-phase proteins such as CRP. Tocilizumab, an anti-human IL-6 receptor, was approved for the treatment of RA, and it reduced disease activity and radiographic joint damage. 7 IL-1 acts as a key mediator in the pathogenesis of RA, and it is expressed in abundance in the synovial membrane. An IL-1 blockade is advantageous in the context of RA. Anakinra, 8 a recombinant version of the IL-1 receptor antagonist (IL-1Ra), was approved for treating refractory RA to DMARDs and for neonatal-onset multisystem inflammatory disease, which is part of the CAPS (cryopyrin-associated periodic syndromes) spectrum. Rilonacept 9 is a dimeric fusion protein consisting of the extracellular domains of the IL-1 receptor and IL-1 receptor accessory protein joined at the constant region (Fc) of human IgG1. By incorporating both components of the IL-1 binding complex, rilonacept, an IL-1 inhibitor, is able to bind tightly to IL-1 with picomolar affinity. Rilonacept was approved for only the treatment of patients with rare genetic conditions called CAPS, but those with various inflammatory syndromes are also treated with rilonacept. The mAb canakinumab, 10 a human monoclonal antibody that targets IL-1β, was approved for the treatment of CAPS and for the treatment of systemic-onset jejunoileal arthropathy. According to the data mentioned above, treatments for a range of the agents blocking IL-1 are derived from classic rheumatic diseases, such as RA and gout, to autoinflammatory syndromes, such as systemic jejunoileal arthropathy. Compared with the pathogenesis of autoimmune diseases, the pathogenesis of autoinflammatory syndromes does not revolve around the recognition of self-antigens by dysfunctional T lymphocytes or autoantibodies. 11 Autoimmune diseases are treated with different cytokine-blocking agents, neutralizing antibodies and inhibitors of cell migration, while autoinflammatory diseases are characteristically responsive to an IL-1 blockade.
Ebosin, a novel EPS (exopolysaccharid), was isolated from the supernatant of the fermentation culture of Streptomyces sp.139, which was collected from soil samples in China. It was revealed that it was a heteropolysaccharide consisting of galactose, fucose, mannose, arabinose, xylose, rhamnose, glucose and galacturonic acid. 12 The biosynthesis gene cluster (ste) of ebosin consisting of 27 ORF (open reading frame) was identified. The individual roles of these genes were subjected to investigation. 13 Aiming to generate derivatives of ebosin with better activities, we carried out the heterologous gene replacement in Streptomyces sp.139 that produce ebosin. We have studied the bioactivities of ebosin both in vitro and in vivo. The effect of ebosin on CIA (collagen-induced arthritis) development was investigated in a rat model. These results showed that ebosin suppresses the development of rat CIA after it was orally administered. 14 This finding was further confirmed by histologic staining, in which significant pathological changes were marked. In the ebosin-treated CIA rats, the levels of IL-1β and TNF-α were notably lower compared with those of untreated controls. In cultured FLS, significant inhibition of IL-1β, TNF-α and IL-6 production was detected at both the mRNA and protein levels after treatment with ebosin. Ebosin also decreased the activities of converting enzymes for IL-1β and TNF-α. The ebosin-triggered inhibition of IL-1β, TNF-α and IL-6 production can be attributed to its therapeutic effect on RA in the CIA rats. Zhang et al. 15 recently identified the effects of ebosin on the NF-κB and MAPK signaling pathways, which are mediated through IL-1β, in rat FLS. These results showed that ebosin reduced the production of phosphorylated p38, c-Jun N-terminal kinase 1 (JNK1), JNK2, the IκB kinase-α (IKKα), IKKβ and IκB in the cytoplasm and NF-κB in the nucleus of FLS treated with ebosin in culture. The outcomes also revealed that ebosin suppressed the DNA-binding activity of NF-κB in the nucleus and inhibited the translocation of NF-κB from the cytoplasm into the nucleus in FLSs. Meanwhile, the levels of the metalloproteinases MMP-1 and MMP-3 and chemokines, including IL-8 and RANTES, were reduced by ebosin in FLS too (Figure 1) . The effects of ebosin on the JAK-STAT, NF-κB and MAPK signaling pathways, which are mediated through IL-6 and TNF-α, in FLS have been studied. The results revealed that ebosin inhibited the TNF-α-induced MAPK and NF-κB signal pathways and blocked the IL-6-triggered JAK-STAT signal pathway by reducing the phosphorylation of JAK2, STAT1, and STAT3 and the translocation of STAT3 into the nucleus (unpublished Figure 1 The effects of ebosin on the MAPK and NF-κB signaling pathways, which are mediated by interleukin-1β. NF-κB and MAPK play essential roles in RA through the regulation of the expression of a large number of genes that contribute to inflammation and bone damage. Ebosin reduces the production of phosphorylated p38, JNK1, JNK2, IKKα, IKKβ and IκB in the cytoplasm and NF-κB in the nucleus of FLS. It inhibits the DNA-binding activity of NF-κB in the nucleus and suppresses the translocation of NF-κB from the cytoplasm into the nucleus. The levels of the metalloproteinases MMP-1 and MMP-3 and chemokines, including IL-8 and RANTES, are also decreased by ebosin in FLS. IKK, the IκB kinase; IκB, inhibitor of NF-κB; IL-1β, interleukin-1β; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MMP, matrix metalloproteinases; NF-κB, nuclear factor kappa B; RA, rheumatoid arthritis; RANTES, reduced upon activation normal T expression and secretion. data). All of the outcomes provide further evidence for understanding the medicinal activity of ebosin at the molecular level. The health value of EPS has been reported several times in recent years, with reports to indicate that EPS can confer health benefits to consumers arising from their immunogenic and cholesterol-lowering properties and so on. It is well-known that the production of IL-1β and its function are closely associated with NLRP3 and other inflammasomes. 16, 17 The potential association of ebosin with inflammasomes needs to be further investigated in the future. Taken together, as a novel EPS, ebosin has the potential to be developed as a new therapeutic agent for the treatment of rheumatoid arthritis and autoinflammatory syndromes.
